Limits...
Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders.

Yoo HK, Lee JS, Paik KW, Choi SH, Yoon SJ, Kim JE, Hong JP - Eur Child Adolesc Psychiatry (2010)

Bottom Line: Total tic scores as measured by the YGTSS decreased over time in both groups (p < 0.001) without any significant differences between groups.These results indicate that aripiprazole may be a promising drug in the treatment of children and adolescents with tic disorders.Further controlled studies are needed to determine the efficacy and tolerability of aripiprazole in these patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu, Seoul 138-736, South Korea. hiyoo@amc.seoul.kr

ABSTRACT
Due to its unique pharmacodynamic properties of dopamine partial agonist activity, and its association with few and mild side effects, aripiprazole is a candidate atypical antipsychotic for patients with tic disorders. This open-label study compared the efficacy and tolerability of aripiprazole with haloperidol, a typical antipsychotic widely used to treat patients with tic disorders. Forty-eight children and adolescents with tic disorders were recruited from the outpatient clinic at South Korea and treated with aripiprazole (initial dose, 5.0 mg/d; maximum dose 20 mg/d) or haloperidol (initial dose, 0.75 mg/d; maximum dose, 4.5 mg/d) for 8 weeks. Treatment efficacy was measured using the yale global tic severity scale (YGTSS), and tolerability was measured using the extrapyramidal symptom rating scale (ESRS) and an adverse effects checklist. Total tic scores as measured by the YGTSS decreased over time in both groups (p < 0.001) without any significant differences between groups. ESRS scores were significantly higher in the haloperidol group during the 4 weeks after commencement of medication (p < 0.05). These results indicate that aripiprazole may be a promising drug in the treatment of children and adolescents with tic disorders. Further controlled studies are needed to determine the efficacy and tolerability of aripiprazole in these patients.

Show MeSH

Related in: MedlinePlus

a Percentage changes in total tic scores over time in the aripiprazole and haloperidol treatment groups. b Percentage changes in motor tic scores over time in the aripiprazole and haloperidol treatment groups. c Percentage changes in phonic tic scores over time in the aripiprazole and haloperidol treatment groups The error bars refer to standard deviation
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3046348&req=5

Fig1: a Percentage changes in total tic scores over time in the aripiprazole and haloperidol treatment groups. b Percentage changes in motor tic scores over time in the aripiprazole and haloperidol treatment groups. c Percentage changes in phonic tic scores over time in the aripiprazole and haloperidol treatment groups The error bars refer to standard deviation

Mentions: At baseline and at each follow-up visit, there were no significant between-group differences in tic scores, indicating that these two drugs were similarly efficacious in reducing tic symptoms (Table 2). After 8 weeks of treatment, 54.3% of the aripiprazole and 63.4% of the haloperidol group showed reductions in total tic scores. Total tic score decreased over time in both groups (Z = −9.60, p < 0.001) (Table 2). This reduction was particularly marked at the first follow-up visit (week 2) in both groups (p < 0.001) and was sustained throughout the study period (Fig. 1a). There were no significant between-group effects or interactions.Table 2


Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders.

Yoo HK, Lee JS, Paik KW, Choi SH, Yoon SJ, Kim JE, Hong JP - Eur Child Adolesc Psychiatry (2010)

a Percentage changes in total tic scores over time in the aripiprazole and haloperidol treatment groups. b Percentage changes in motor tic scores over time in the aripiprazole and haloperidol treatment groups. c Percentage changes in phonic tic scores over time in the aripiprazole and haloperidol treatment groups The error bars refer to standard deviation
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3046348&req=5

Fig1: a Percentage changes in total tic scores over time in the aripiprazole and haloperidol treatment groups. b Percentage changes in motor tic scores over time in the aripiprazole and haloperidol treatment groups. c Percentage changes in phonic tic scores over time in the aripiprazole and haloperidol treatment groups The error bars refer to standard deviation
Mentions: At baseline and at each follow-up visit, there were no significant between-group differences in tic scores, indicating that these two drugs were similarly efficacious in reducing tic symptoms (Table 2). After 8 weeks of treatment, 54.3% of the aripiprazole and 63.4% of the haloperidol group showed reductions in total tic scores. Total tic score decreased over time in both groups (Z = −9.60, p < 0.001) (Table 2). This reduction was particularly marked at the first follow-up visit (week 2) in both groups (p < 0.001) and was sustained throughout the study period (Fig. 1a). There were no significant between-group effects or interactions.Table 2

Bottom Line: Total tic scores as measured by the YGTSS decreased over time in both groups (p < 0.001) without any significant differences between groups.These results indicate that aripiprazole may be a promising drug in the treatment of children and adolescents with tic disorders.Further controlled studies are needed to determine the efficacy and tolerability of aripiprazole in these patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu, Seoul 138-736, South Korea. hiyoo@amc.seoul.kr

ABSTRACT
Due to its unique pharmacodynamic properties of dopamine partial agonist activity, and its association with few and mild side effects, aripiprazole is a candidate atypical antipsychotic for patients with tic disorders. This open-label study compared the efficacy and tolerability of aripiprazole with haloperidol, a typical antipsychotic widely used to treat patients with tic disorders. Forty-eight children and adolescents with tic disorders were recruited from the outpatient clinic at South Korea and treated with aripiprazole (initial dose, 5.0 mg/d; maximum dose 20 mg/d) or haloperidol (initial dose, 0.75 mg/d; maximum dose, 4.5 mg/d) for 8 weeks. Treatment efficacy was measured using the yale global tic severity scale (YGTSS), and tolerability was measured using the extrapyramidal symptom rating scale (ESRS) and an adverse effects checklist. Total tic scores as measured by the YGTSS decreased over time in both groups (p < 0.001) without any significant differences between groups. ESRS scores were significantly higher in the haloperidol group during the 4 weeks after commencement of medication (p < 0.05). These results indicate that aripiprazole may be a promising drug in the treatment of children and adolescents with tic disorders. Further controlled studies are needed to determine the efficacy and tolerability of aripiprazole in these patients.

Show MeSH
Related in: MedlinePlus